BIO-PATH HOLDINGS, INC. (BPTH): Nasdaq/NYSE listing notice — Bio-Path receives Nasdaq bid-price deficiency notice; shareholders OK reverse split

BIO-PATH HOLDINGS, INC.

Nasdaq letter Dec 12, 2024: closing bid below $1 for 30 straight days; 180 days until June 10, 2025 to comply.
Stockholders approved reverse stock split up to 1-for-30 to potentially cure deficiency.
Approved increase in 2022 Stock Incentive Plan shares by 1,200,000 to total 1,265,000 shares.
Ratified Ernst & Young as independent auditor for fiscal year ending Dec 31, 2024.
All five director nominees elected with over 80% of votes cast for each.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

BIO-PATH HOLDINGS, INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

December 12, 2024, Bio-Path Holdings, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar day

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

BIO-PATH HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-128517

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.